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Protracted venous infusion 5-fluorouracil (5FU) combined with mitomycin C (MMC) has demonstrated significant activity against
metastatic colorectal cancer. Owing to potential synergy based upon upregulation of thymidine phosphorylase by MMC, the
combination of capecitabine and MMC may improve outcomes in irinotecan-refractory disease. Eligible patients with progressive
disease during or within 6 months of second-line chemotherapy were treated with capecitabine (1250mgm
 2 twicedaily)days1–14
every 3 weeks and MMC (7mgm
 2 IV bolus) once every 6 weeks. A total of 36 patients were recruited, with a median age of 64
years (range 40–77), and 23 patients (78%) were performance status 0–1. The objective response rate was 15.2%. In all, 48.5% of
patients had stable disease. Median failure-free survival was 5.4 months (95% CI 4.6–6.2). Median overall survival was 9.3 months
(95% CI: 6.9–11.7). Grade 3 toxicities were palmar-plantar erythema 16.7%, vomiting 8.3%, diarrhoea 2.8%, anaemia 8.3%, and
neutropenia 2.8%. No patients developed haemolytic uraemic syndrome. Symptomatic improvement occurred for pain, bowel
symptoms, and dyspnoea. Capecitabine in combination with MMC is an effective regimen for metastatic colorectal cancer resistant to
5FU and irinotecan with an acceptable toxicity profile and a convenient administration schedule.
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Colorectal cancer (CRC) is one of the most common tumours
worldwide, with approximately 1 million new cases diagnosed
in 2000 accounting for over 500000 deaths. At some stage during
the course of the disease, 40–50% of patients develop metastatic
disease. While effective agents are available for the first- and
second-line treatment of metastatic CRC, there are relatively few
published data on third-line therapies.
Capecitabine is a fluoropyrimidine prodrug that is metabolised
to 5-fluorouracil (5FU) in a three-step process (Ishikawa et al,
1998). The last step requires thymidine phosphorylase, which is
significantly more active in tumour compared to normal tissues.
Hence, the conversion of capecitabine to active metabolite occurs
preferentially at tumour sites. This may partially explain the
differing toxicity profile compared to intravenous 5FU. Capecita-
bine monotherapy has been shown in randomised studies to be
at least equivalent to bolus 5FU in terms of response rate, time to
tumour progression, and overall survival (OS) for previously
untreated metastatic CRC (Hoff et al, 2001; Van Cutsem et al,
2001). Owing to greater patient convenience, capecitabine has been
substituted for short-duration bolus/infusion 5FU/leucovorin
(LV5FU2) in combination schedules of oxaliplatin and irinotecan
(Cassidy et al, 2004; Jordan et al, 2004).
Mitomycin C (MMC) is an antitumour antibiotic that has
modest single-agent activity in patients with metastatic CRC
(Hartmann et al, 1998; Anderson et al, 1999). A randomised study
of 320 patients with untreated advanced CRC compared protracted
venous infusion of 5FU (PVI 5FU) plus MMC and circadian-timed
infusion of 5FU plus MMC (Price et al, 2004). This demonstrated
a response rate of 38% and a median survival of 15.8 months in
the PVI 5FU plus MMC arm. A previous study of 200 patients
randomised to PVI 5FU plus MMC or PVI 5FU alone demonstrated
an improved response rate in the combination arm (54 vs 38%,
P¼0.024) (Ross et al, 1997). However, there was no difference in
OS. Another study of 24 patients with advanced CRC described a
12.5% response rate and median survival of 9.0 months using
second-line PVI 5FU and MMC (Chester et al, 2000).
There is in vivo evidence of MMC-induced upregulation of
intratumoral thymidine phosphorylase, which is the critical
enzyme for the conversion of capecitabine to 5FU (Sawada et al,
1998). Hence, there is the possibility of clinically significant
synergy between capecitabine and MMC. The capecitabine/MMC
combination has been tested in patients with previously untreated
metastatic CRC. A phase II study evaluated this combination in 92
first-line patients (Rao et al, 2004). Of 84 patients evaluable for
response, the objective response rate was 38%, with a median OS
of 14.3 months. The most frequent grade 3/4 toxicity was palmar-
plantar erythema, which occurred in 19.7% of patients. There is
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slimited data available on the capecitabine/MMC combination in
patients with pretreated mestatatic CRC. A dose-escalation study
enrolled 25 patients with pretreated advanced CRC (Hofheinz et al,
2004). Two patients (8%) achieved partial responses and the
median progression-free survival was 2.0 months.
A significant proportion of patients with metastatic CRC are
eligible for further chemotherapy following failure of two previous
regimens. Given the encouraging efficacy and tolerability of
capecitabine plus MMC in patients with treatment-naı ¨ve metastatic
CRC, and the relative lack of data in pretreated patients, we
conducted a phase II study in patients who had previously received
two lines of chemotherapy for metastatic disease.
PATIENTS AND METHODS
We conducted a phase II open-label study between July 2001 and
November 2003 at two centres, one in the UK and one in Australia.
The study was approved by both local medical ethics committees.
Written, informed consent was obtained from each patient.
Eligibility criteria
Inclusion criteria included histologically proven advanced or
metastatic, inoperable adenocarcinoma of the colon or rectum,
documented disease progression during or within 6 months
following treatment with both 5FU and irinotecan, bidimensionally
measurable disease as assessed by computed tomography (CT)
scanning outside any previously irradiated area; ECOG perfor-
mance status 0, 1, or 2; absence of any uncontrolled, concurrent
medical conditions other than nonmelanotic skin cancer or
carcinoma in situ of the uterine cervix, and life expectancy of
greater than 3 months. Adequate baseline organ function was
defined as follows: bone marrow (platelets 4100 10
9l
 1, WBC
43 10
9l
 1, neutrophils 41.5 10
9l
 1), renal (creatinine clear-
ance 430mlmin
 1), and hepatic (serum total bilirubin o1.5 
upper limit of normal range). Before entry into the study, all
patients were required to have a CT scan of the chest, abdomen,
and pelvis and carcinoembryonic antigen (CEA) measurement.
Chemotherapy
The selected chemotherapy regimen was identical to that used in
a previous study which demonstrated safety and efficacy in
previously untreated patients with advanced CRC (Rao et al, 2004).
Mitomycin C was delivered as an intravenous bolus at a dose
of7mgm
 2 every 6 weeks. Capecitabine (2500mgm
 2day
 1) was
administered orally in two divided doses for 14 days followed by a
7-day treatment-free interval. Each capecitabine cycle was repeated
every 21 days. Patients continued therapy for 12 weeks and were
then reassessed. If there was no evidence of disease progression,
treatment was then continued for a further 12 weeks. The
maximum duration of therapy was 24 weeks.
Toxicity evaluation and dose modification
Toxicity was evaluated and graded according to the National
Cancer Institute Common Toxicity Criteria (Version 2.0). For
grade 3 nonhaematological toxicity, capecitabine therapy was
suspended until resolution and reinitiated with a 25% dose
reduction for the first occurrence and 50% for the second. For
grade 4 nonhaematological toxicity, capecitabine therapy was
either terminated or suspended until resolution, with a 50% dose
reduction upon reinitiation at the treating physician’s discretion.
For haematological toxicity, if the absolute neutrophil count was
less than 1.0 10
9 l
 1 or the platelet count was less than
100 10
9l
 1, capecitabine and MMC were delayed until resolution
and reinitiated at full dose for a 1-week delay or with a 25% dose
reduction for a 2-week delay.
Efficacy evaluation
Tumour response was investigator-assessed by CT scan according
to RECIST criteria at 12 and 24 weeks. Eastern Co-operative
Oncology Group performance status (PS) was assessed at baseline,
12 weeks, and 24 weeks after commencement of chemotherapy and
every 3 months thereafter until death or disease progression.
Failure-free survival (FFS) and OS were calculated for all patients
from the date of treatment commencement. Failure-free survival
was defined as time to tumour progression or death from any
cause. Overall survival was defined as time to death from any
cause. The method of Kaplan and Meier was used. Symptoms of
dysphagia, reflux, pain, anorexia, weight loss, nausea, vomiting,
altered bowel habit, lethargy, and dyspnoea were prospectively
documented as present or absent at baseline and throughout the
treatment period. Symptoms that resolved from present to absent
during the course of therapy were coded as symptomatic response
for that parameter.
Statistical methods
This phase II study was constructed using the Simon optimal
two-stage design. The sample size was calculated with 90% power
to detect an objective response rate of 20% and to rule out a
response rate of 5% using a one-sided test. The first stage was
determined to be 21 patients, after which an interim analysis was
performed. The criterion for continued accrual was the observa-
tion of at least one tumour response. The second stage was planned
to accrue a further 20 patients provided this condition was met.
The study was terminated after enrolment of 36 patients due to
slowing accrual.
RESULTS
A total of 36 patients were entered into the study between July 2001
and November 2003. Baseline patient characteristics are presented
in Table 1. The median age was 64 (range 40–77) years. In all,
78% of patients had a PS of 0 or 1. All patients had received
irinotecan as either first- or second-line therapy. Only two patients
had received prior oxaliplatin. No patient had received prior
capecitabine.
Chemotherapy delivery
The median treatment duration was 18.5 weeks (range 1–28). The
median dose intensity for capecitabine was 81.5% of the starting
dose.
Tumour and symptomatic response
A total of 33 patients were evaluable for response. Three patients
who withdrew from the study for logistical reasons prior to
response assessment were not evaluable for response. The overall
response rate was 15.2%. In all, 48.5% had stable disease.
Improvement in tumour-related symptoms was observed in a
substantial proportion of patients who had baseline pain, lethargy,
dyspnoea, altered bowel habit, anorexia, or weight loss (Tables 2
and 3).
Toxicity
Capecitabine/MMC was a well-tolerated regimen with no grade 4
toxicity experienced by any patient. All grade 3 toxicities are
presented in Table 4. Grade 3 haematological toxicities were
anaemia (8.3%), neutropenia (2.8%), and thrombocytopenia
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s(2.8%). The most frequent grade 3 nonhaematological toxicities
were palmar-plantar erythema (16.7%), nausea/vomiting (8.3%),
and lethargy (5.6%). Two patients (5.6%) developed grade 2 chest
pain thought to be related to capecitabine and were therefore taken
off study. One patient developed tumour-related hydronephrosis;
therefore MMC was ceased. There were no cases of red cell
fragmentation requiring cessation of MMC, and no cases of
haemolytic uraemic syndrome were observed.
Survival
At the time of analysis, survival data were complete, with no
surviving patients. The median overall survival was 9.3 months
(95% CI: 6.9–11.7) with a 1-year survival of 30.6% (Figure 1). The
median FFS was 5.4 months (95% CI: 4.6–6.2) (Figure 2). A total
of 11 patients went on to receive fourth-line treatment following
completion of this study; eight received oxaliplatin.
Table 1 Patient characteristics
Patient characteristics Number (%)
Total enrolled 36
Median age (years) (range) 64 (40–77)
Male:female 21:15
ECOG performance status
0 10 (27.8)
1 18 (50.0)
2 8 (22.2)
Primary site
Colon 27 (75)
Rectum 9 (25)
Sites of metastases
Liver 31 (86.1)
Lung 14 (38.9)
Nodal 6 (16.7)
Peritoneum 6 (16.7)
Locoregional 5 (13.9)
Histological differentiation
Moderate 29 (80.6)
Poor 4 (11.1)
Unknown 3 (8.3)
Previous first-line therapies
5-Fluorouracil 35
UFT 1
Oxaliplatin 2
Irinotecan 1
Previous second-line therapies
Irinotecan 35
Cetuximab 1
Table 2 Tumour response to capecitabine/MMC
Best response Number of patients %
CR 0 0
PR 5 15.2
SD 16 48.5
PD 12 36.4
NE 3
CR¼complete response; PR¼partial response; SD¼stable disease; PD¼progres-
sive disease; NE¼not evaluable.
Table 3 Symptom response to capecitabine/MMC
Symptom
Proportion of patients with baseline
symptoms resolving on therapy %
Pain 14/18 77.8
Lethargy 9/22 40.9
Altered bowel habit 7/10 70
Dyspnoea 5/6 83.3
Anorexia 3/6 50
Weight loss 2/4 50
Table 4 Toxicity
Toxicity All grades (n¼36) (%) Grade 3 (%)
Palmar-plantar erythema 50 16.7
Nausea/vomiting 44.5 8.3
Lethargy 94.5 5.6
Diarrhoea 52.8 2.8
Peripheral neuropathy 8.3 2.8
Fever 8.6 2.8
Stomatitis 33.3 0
Infection 11.1 0
Anaemia 61.1 8.3
Neutropenia 11.1 2.8
Thrombocytopenia 16.7 2.8
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Figure 1 Survival.
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Figure 2 Failure-free survival.
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sDISCUSSION
The combination of capecitabine and MMC is efficacious,
results in symptom relief and is well tolerated as third-line
treatment of metastatic CRC. This is consistent with the observed
efficacy of the same regimen when administered to patients
with untreated advanced CRC (Rao et al, 2004). The demonstrated
activity of capecitabine/MMC in this study contrasts with the
lack of response to capecitabine monotherapy seen in a phase II
study of 5FU-refractory advanced colorectal cancer (Hoff et al,
2004). Capecitabine/MMC therefore represents a plausible
regimen for those patients who are eligible for treatment after
failure of two previous regimens. In the current era of targeted
therapies, capecitabine/MMC may be a reasonable alternative if
targeted therapies such as cetuximab are unavailable or contra-
indicated.
The observed objective response rate of 15.2% and median
overall survival of 9.3 months in this study compares favourably
with other trials of patients with advanced CRC previously treated
with 5FU and irinotecan. Kemeny et al performed a randomised
study in which 214 patients who had previously received sequential
5FU and irinotecan received either bolus/infused 5FU/LV
(LV5FU2) or oxaliplatin/LV5FU2 (FOLFOX4) as third-line treat-
ment for advanced CRC. An objective response rate of 13% and a
median survival of 9.9 months were found in patients receiving
FOLFOX4 (Kemeny et al, 2004). The response rate in patients
receiving LV5FU2 was only 2%. However, the median survival
(11.4 months, P¼0.2) was similar for patients randomised to
receive LV5FU2, which could have been due to protocol-permitted
crossover to FOLFOX4 in patients with progressive disease on
LV5FU2. In fact, 69% of patients in the LV5FU2 arm subsequently
received oxaliplatin upon tumour progression.
These data are important for the interpretation of our
capecitabine/MMC median survival, as they imply that whether
oxaliplatin was given third- or fourth-line, the OS was similar.
Therefore, although only 22% of our patients went on to
subsequent fourth-line oxaliplatin, the median survival of patients
receiving capecitabine/MMC third-line was consistent with that
observed for oxaliplatin or LV5FU2 given third-line in the Kemeny
study. Tumour response rates were also similar for capecitabine/
MMC and FOLFOX4 across the two studies. One potential
advantage, however, of delaying oxaliplatin use may be to reduce
the impact of oxaliplatin-induced sensory neuropathy.
Of note, the capecitabine/MMC regimen used in our cohort
appears to have similar or greater efficacy than the combination of
raltitrexed and MMC given as third-line treatment for metastatic
CRC. A study of 21 patients who had all previously received 5FU,
irinotecan, and oxaliplatin were treated with raltitrexed plus MMC
on a 4-week schedule (Rosati et al, 2003). Of 16 patients evaluable
for response, there were no objective tumour responses, although
33.6% had stable disease. The median overall survival was 5
months. While the patients in our study had generally not received
oxaliplatin as first- or second-line treatment, as discussed above,
the order in which a patient receives cytotoxic agents may not
impact on OS times.
Another study of capecitabine/MMC in patients with oxaliplatin
and irinotecan-refractory advanced colorectal cancer supports the
activity of this combination as third-line therapy. In total, 20
response-evaluable patients were treated with capecitabine
2000mgm
 2 days 1–14 every 3 weeks and MMC 7mgm
 2 every
6 weeks (Harba et al, 2003). A total of 10% achieved a partial
response and the median OS was 7.75 months. Of note, the
capectabine dose was 20% lower than in our study. Another study
using the same schedule as Harba et al also demonstrated a 4.8%
response rate and median survival of 6.8 months in the third-line
setting (Lim do et al, 2005).
Therapies targeting signalling transduction pathways such as
the epidermal growth factor receptor (EGFR) pathway are
currently being studied in advanced CRC. The BOND study
randomised 329 EGFR-expressing irinotecan-refractory patients to
irinotecan and cetuximab or cetuximab alone (Cunningham et al,
2004). The majority of patients had received two or more previous
lines of chemotherapy, although 20.7% had only received one
previous chemotherapy regimen. While the response rate in
patients receiving combination therapy was 22.9%, that for the
cetuximab monotherapy arm was 10.8%. Overall survival was
8.6 months in the combination arm and 6.9 months in the
monotherapy arm. It is interesting to note that in our study,
capecitabine/MMC appeared to have comparable response rate to
cetuximab monotherapy in patients pretreated with 5FU followed
by irinotecan.
The relatively low toxicity experienced by patients receiving
capecitabine and MMC is attractive for patients eligible for third-
line therapy for metastatic CRC. Patients often have substantial
cumulative toxicities from previous chemotherapy, and may be of
poorer performance status than those eligible for first-line therapy.
Additional toxicity from MMC was essentially limited to greater
myelosuppression than would be expected for capecitabine
monotherapy. However, no episodes of grade 3 infection were
observed. There were no cases of haemolytic uraemic syndrome
observed in our cohort all of whom had normal baseline renal
function. The acceptable toxicity profile is reinforced by the
observation that 11 patients were fit enough subsequently to go
onto fourth-line therapy.
In conclusion, the combination of capecitabine and MMC is
active and well tolerated as third-line therapy in patients who are
refractory to irinotecan. Our study has demonstrated tumour
response rate and survival data that are comparable to other third-
line therapeutic options, such as oxaliplatin or cetuximab-based
regimens. Capecitabine and MMC could therefore be considered
as a third-line treatment option if patients are not eligible for
treatment with these regimens.
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